Syndax says mid-stage trial of lung disease treatment fails main goal, ends development

Syndax says mid-stage trial of lung disease treatment fails main goal, ends development ReutersSyndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis GlobeNewswireSyndax Pharmaceuticals stock tumbles on failed IPF trial By Investing.com Investing.com IndiaSyndax’s axatilimab fails primary endpoint in pulmonary fibrosis trial By Investing.com Investing.com India

This page contains an attributed headline and the preview text supplied through the publisher’s RSS feed. Copyright in the original reporting belongs to Google News — Business.